The loss of expression of particular microRNAs can contribute to tumorigenesis. Kota et al. (2009) now explore in a mouse model a promising new approach for the treatment of liver cancerre-establishing the expression of an miRNA using a viral vector.
looks as if it may have to be abandoned because Scherrer et al. show that DOR is not expressed in substance P-containing neurons. In addition, it looks like it behaves as a prototypic GPCR with membrane expression in basal conditions and internalization on activation, rather than the use-dependent insertion into the membrane suggested in current models.
What has so muddied the waters? It turns out that perhaps all commercially available antibodies raised against DOR peptides recognize a protein that is still present in mice lacking DOR and all immunohistochemistry using these antibodies is therefore suspect. Scherrer et al. use a DOR-enhanced green fluorescent protein (EGFP) reporter mouse to show that the receptor is localized in the set of presumptive nociceptor neurons that do not express substance P. The often made jest that the most valuable contribution of knockouts is to test antibody specificity is not a joke. What protein these antibodies recognize and its involvement in opioid receptor biology are now open questions, as is how substance P may contribute to morphine tolerance. DOR reporters with Myc and hemagluttinin tags are expressed in LDCVs whereas those with a smaller GFP tag are located on the cell surface and interact with agonists (Wang et al., 2008) , a further source of potential artifact.
Scherrer et al. argue that expression of MOR in TRPV1-expressing nociceptor neurons contributes to analgesia for heat pain whereas DOR action in nonpeptidergic sensory neurons results in reduction only in mechanical pain. These results are intriguing, suggesting that although most nociceptors are activated by both heat and mechanical stimuli, the input somehow and unexpectedly enters the CNS via anatomically distinct channels. This appears difficult to reconcile though with the very substantial clinical experience that morphine's analgesic actions are not limited to heat pain and the observation that DOR agonists can very effectively reduce heat pain after peripheral inflammation (Codd et al., 2009 ). Many exciting questions remain, not least whether DOR agonists will join MOR agonists in the pantheon of clinically useful opiate analgesics if their propensity to induce seizures can be fully overcome.
The vascular system comprises an elaborate network of arteries, capillaries, and veins that penetrate all body tissues to provide oxygen and nutrients and to remove waste. During development, new blood vessels form by sprouting into avascular zones in a process known as angiogenesis. The primary driver of angiogenesis is hypoxia (lack of oxygen). Hypoxia accompanies tissue growth and triggers the release of angiogenic growth factors, the best studied of which is vascular endothelial growth factor (VEGF). Endothelial cells line blood vessels and normally rest in a quiescent state. In response to VEGF, they become activated and promote the sprouting of new vessels. The tips of these sprouts are formed by specialized endothelial cells called tip cells (Figure 1 (Siekmann et al., 2008) . In this issue of Cell, Benedito et al. (2009) gain insight into the regulation of the balance between tip cell and stalk cell specification during angiogenesis. Why do some endothelial cells become tip cells and others stalk cells? Genetic studies in mice and zebrafish have established that VEGF receptor signaling is the primary stimulator of tip cell formation, whereas Notch signaling provides a counteracting inhibitory signal. The transmembrane Notch ligand Delta-like 4 (Dll4) has a key role in tip cell specification. Its expression is induced in tip cells by VEGF, and perturbation of Dll4 by genetic lossof-function mutation or by pharmacological inhibition results in excessive tip cell formation and angiogenesis. This indicates that Dll4 normally signals to adjacent cells, likely through Notch1, to suppress the tip cell phenotype (Phng and Gerhardt, 2009) . Through this process, a single tip cell is selected from among several candidate endothelial cells to lead a new vessel sprout. Evidence suggests that this determination of tip cell versus stalk cell fate occurs through Notch regulation of VEGF receptor expression, thus allowing for precise coordination of the response to the VEGF signal ( Figure  1 ). The fine balance between these proand antiangiogenic pathways enables all blood vessels to respond to a localized need for new vessel growth but keeps such growth under tight control. Benedito et al. now show that the Notch ligand Jagged1 (Jag1), which has not been associated with sprouting angiogenesis, can shift this balance to promote new vessel growth by antagonizing Dll4-mediated Notch signaling.
Benedito et al. use loss-of-function and gain-of-function mouse models to investigate the role of Jag1 in retinal angiogenesis. As global deletion of Jag1 causes embryonic lethality (Xue et al., 1999) , the authors use a mouse model in which Jag1 is selectively lost in endothelial cells. In these mice, retinal angiogenesis is impaired, exhibiting a lower density of blood vessels and fewer tip cells. Conversely, overexpression of Jag1 in retinal endothelial cells leads to increased angiogenesis and more tip cells. Thus, in contrast to Dll4, which suppresses angiogenesis and tip cell formation, Jag1 promotes angiogenesis. Does Jag1 also act via Notch? Benedito and colleagues find that expression of the Notch target genes Hey1 and Hes1 increases when Jag1 is deleted in endothelial cells. This indicates that Notch signaling is more active in the absence of Jag1, with a corresponding inhibitory effect on vessel growth. If Notch signaling is blocked in these mice by a pharmacological inhibitor of Notch, angiogenesis and tip cell formation are induced. This evidence suggests that Jag1 negatively regulates Notch activity. The authors further propose that Jag1 antagonizes Dll4-mediated Notch activation. The complementary expression patterns of Jag1 and Dll4 in sprouting blood vessels support such a hypothesis. Jag1 is expressed in stalk cells but is absent or exhibits reduced expression in tip cells. In contrast, Dll4 is strongly expressed in tip cells; it is expressed at lower levels in stalk cells (Figure 1) Vascular endothelial growth factor (VEGF) produced by hypoxic cells activates endothelial cells to form a new blood vessel sprout. A sprouting blood vessel is composed of one tip cell and many stalk cells. VEGF induces expression of Delta-like 4 (Dll4) in the tip cell, which signals to stalk cells to activate Notch downstream targets and to reduce VEGF receptor expression levels, thereby suppressing tip cell fate. In the stalk cell, the glycosyltransferase Fringe modifies Notch receptors to enhance Notch signaling induced by Dll4 from the tip cell, further reducing stalk cell VEGF receptor (VEGFR) levels and perhaps inducing quiescence. However, Jagged-1 (Jag1) in the stalk cell can antagonize Dll4-Notch signaling to maintain an activated stalk cell phenotype that is responsive to VEGF, thereby promoting angiogenesis. Stalk cells also express low levels of Dll4. Fringe could allow for Jag1 to inhibit possible Dll4-mediated signaling between stalk cells or from stalk cells to the tip cell. In tip cells lacking Fringe, Jag1 might promote angiogenesis by signaling directly to Notch to induce VEGFR3 expression.
Notch activation. These observations in cultured cells are relevant in vivo, as residual levels of Dll4 that could potentially suppress angiogenesis are present in stalk cells. By antagonizing these signals, Jag1 can promote stalk cell activation and maintain the VEGF response. Supporting evidence for Fringe-mediated regulation of angiogenesis also comes from genetic deletion of another Fringe family member, Lunatic Fringe, in mice. Loss of Lunatic Fringe results in enhanced retinal angiogenesis and increased tip cell numbers, indicating reduced Notch activation.
In addition to antagonizing Dll4-mediated activation of Notch signaling, Jag1 could also promote angiogenesis by signaling directly to tip cells to regulate the expression of VEGF receptor 3 (VEGFR3). VEGFR3 has a crucial role in mediating the growth of lymphatic vessels, but it is also expressed in endothelial tip cells where it promotes angiogenesis. Indeed, a recent study has shown that disruption of VEGFR3 function in endothelial tip cells using monoclonal antibodies blocks vascular sprouting (Tammela et al., 2008) . Benedito et al. show that VEGFR3 expression in tip cells is decreased when Jag1 is deleted, providing a mechanistic explanation for why these tip cells could have an impaired sprouting response. Thus, one could envision that, just as Dll4-Notch signaling downregulates expression of the VEGF receptor in stalk cells to inhibit vessel growth, Jag1-Notch signaling could upregulate VEGFR3 expression in tip cells to promote vessel growth.
A key question arising from this work is how Jag1 and Fringe family members are themselves regulated in endothelial cells. Jag1 expression can be induced in vitro by inflammatory factors such as tumor necrosis factor α, which could provide a means for integrating signals from the local microenvironment to promote new vessel growth (Sainson et al., 2008) . Evidence from the study of Benedito et al. suggests that Fringe is not expressed uniformly in sprouting vessels but is found in subsets of stalk and tip cells. Given the crucial roles that Fringe members could play in regulating angiogenesis, understanding the upstream factors that control their expression will be essential to further unraveling their function. Lastly, Jag1 clearly plays additional roles during angiogenesis beyond those in tip and stalk cell selection, and it also functions in tissues other than blood vessels (Hofmann and Iruela-Arispe, 2007) . In humans, for example, haploinsufficiency of Jag1 causes Alagille Syndrome, which is characterized by abnormalities in the cardiovascular system, liver, eye, and skeleton (Gridley, 2003) . The ability to selectively delete Jag1 in different tissues and at different developmental stages in model organisms should allow more detailed investigation of the pathogenesis of this disease.
MicroRNAs (miRNAs) play fundamental roles in the regulation of gene expression by pairing via partial Watson Crick interactions with complementary sequences within the 3′ untranslated regions (UTRs) of targeted transcripts (Bartel and Chen, 2004; Bartel, 2009 
